Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany | Zendy

Feucht | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany

Author(s) -

Feucht

Publication year - 2008

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s2842

Subject(s) - pegaptanib , medicine , macular degeneration , ophthalmology , choroidal neovascularization , visual acuity , intraocular pressure , ranibizumab , bevacizumab , surgery , chemotherapy

The VEGF Inhibition Study In Ocular Neovascularisation (VISION) reported the efficacy of intravitreal (ITV) vascular endothelial growth factor (VEGF) inhibition with pegaptanib sodium (Macugen((R))) for the treatment of neovascular age-related macular degeneration (AMD). This paper reports clinical experience with pegaptanib sodium for the treatment of occult or minimally classic choroidal neovascularization (CNV) due to AMD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research